Loading...
KEYNOTE-966 trial in progress: Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer
Kelley, R. K. Furuse, J. Edeline, J. Finn, R. S. Ren, Z. Su, S. C. Malhotra, U. Siegel, A. B. Vogel, A.
Kelley, R. K.
Furuse, J.
Edeline, J.
Finn, R. S.
Ren, Z.
Su, S. C.
Malhotra, U.
Siegel, A. B.
Vogel, A.
Citations
Altmetric:
Abstract
Background: Biliary tract cancer (BTC), comprising intra- and extra-hepatic cholangiocarcinoma
and gallbladder cancer, is a rare and aggressive malignancy. Most
patients (pts) present with advanced or unresectable disease, for which the current
standard of care is gemcitabine plus cisplatin. Median survival for these pts is only 12
months, highlighting the need for more effective therapies. Pembrolizumab is a PD-1inhibitor that has demonstrated modest antitumor activity as monotherapy in pts
with previously treated BTC and has improved survival when used in combination
with platinum-based chemotherapy in other cancer types.
Description
Date
2020
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 117.5 KB
Keywords
Type
Meetings and Proceedings
Citation
Valle JW, Kelley RK, Furuse J, Edeline J, Finn RS, Ren Z, et al. 78TiP KEYNOTE-966 trial in progress: Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer. Annals of Oncology. 2020;31:S270-S1.